Search
Cellectis SA
CLLSAdd to Watchlist
3.300USD
+0.360+12.24%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
238.67MMarket Cap
LossP/E TTM
More Details of Cellectis SA Company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Cellectis SA Info
Ticker SymbolCLLS
Company nameCellectis SA
IPO dateFeb 06, 2007
CEOSourdive (David J.D)
Number of employees224
Security typeDepository Receipt
Fiscal year-endFeb 06
Address8, rue de la Croix Jarry
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75013
Phone33181691600
Websitehttps://www.cellectis.com/
Ticker SymbolCLLS
IPO dateFeb 06, 2007
CEOSourdive (David J.D)
Company Executives of Cellectis SA
Name
Name/Position
Position
Shareholding
Change
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephan Reynier
Mr. Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Chief Regulatory and Pharmaceutical Compliance Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Mr. Arthur Stril
Mr. Arthur Stril
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Steven (Steve) Doares, Ph.D.
Dr. Steven (Steve) Doares, Ph.D.
Senior Vice President - US Manufacturing
Senior Vice President - US Manufacturing
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of Cellectis SA?
The top five shareholders of Cellectis SA are: Dr. Andre Choulika, Ph.D.
How many institutions hold shares of Cellectis SA (CLLS)?
As of 2026Q1, 77 institutions hold shares of Cellectis SA, with a combined market value of approximately 12.30M, accounting for 17.00% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5544701.00.